Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze KPTI stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate KPTI investment potential.

What is KPTI stock price today?

Get real-time KPTI stock price, historical data, and price charts on Financhill. Track KPTI performance with our advanced analysis tools.

Is KPTI a good investment?

Evaluate KPTI investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy KPTI stock?

To buy KPTI stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of KPTI?

View detailed market capitalization data and company valuation metrics for KPTI on our comprehensive analysis page.

What is the P/E ratio of KPTI?

Use our fundamental analysis tools to view KPTI P/E ratio and compare valuation metrics with industry peers.

What are KPTI earnings?

View KPTI earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Karyopharm Therapeutics, Inc. 10K Form

Buy

KPTI
Karyopharm Therapeutics, Inc.

Last Price:

$9.68

Seasonality Move:

-14.56%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly
2023-11-02	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly
2023-08-02	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly
2023-05-04	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly
2022-11-03	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly
2022-08-04	10Q	KPTI/Karyopharm Therapeutics, Inc. Quarterly

Receive KPTI News And Ratings

See the #1 stock for the next 7 days that we like better than KPTI

KPTI Financial Statistics

Sales & Book Value

Annual Sales:	$146.1M
Cash Flow:	$-11.8M
Price / Cash Flow:	0
Annual Sales:	$-16.00
Price / Book:	0

Profitability

EPS (TTM):	-16.62100
Net Income (TTM):	$-196M
Gross Margin:	$139.8M
Return on Equity:	0%
Return on Assets:	-160.51%

Karyopharm Therapeutics, Inc. Earnings Forecast

Key Karyopharm Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 15 years for KPTI is 95.72%.
The Selling, General & Administrative Expenses for KPTI have been equal to 72.03% of Gross Profit Margin.
The Research & Development expenses have been 85.80% of Revenue.
The Net Earning history of KPTI is -134.21% of Total Revenues.
Per Share Earnings over the last 15 years have been positive in 6 years.

Karyopharm Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	KPTI
CUSIP:	48576U
Website:	karyopharm.com

Debt

Debt-to-Equity Ratio:	-0.8
Current Ratio:	1.12
Quick Ratio:	0.98

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

KPTI Technical Analysis vs Fundamental Analysis

Buy

Karyopharm Therapeutics, Inc. (KPTI) is a Buy

Is Karyopharm Therapeutics, Inc. a Buy or a Sell?

Karyopharm Therapeutics, Inc. stock is rated a Buy

The current Karyopharm Therapeutics, Inc. [KPTI] share price is $9.67. The Score for KPTI is 74, which is 48% above its historic median score of 50, and infers lower risk than normal.